MOG and demyelinating disease: Antibodies against myelin oligodendrocyte glycoprotein are associated with inflammatory demyelinating diseases contributing to acute myelitis in COVID-19 patients and increasing the risk of developing a chronic or recurrent demyelinating disease in convalescing patients [26].